Clinical trialNCT07218380RecruitingPhase 3Interventional

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

SponsorEli Lilly and CompanyEnrollment450Carcinoma, Transitional CellNeoplasm MetastasisUrinary Bladder Neoplasms

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

290 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Box Hill Hospital
Box Hill, Australia
Iris Tung
Recruiting
Mater Misericordiae Limited
Brisbane, Australia
Niara Oliveira
Recruiting
Genesiscare - Campbelltown
Campbelltown, Australia
Felicia Roncolato
Recruiting
Austin Health
Heidelberg, Australia
Andrew Weickhardt
Recruiting
Macquarie University
Macquarie University, Australia
Alison Zhang
Recruiting
Sir Charles Gairdner Hospital
Perth, Australia
Rajiv Shinde
Recruiting
Prince of Wales Hospital
Randwick, Australia
Elizabeth Hovey
Recruiting
Western Health-Sunshine & Footscray Hospitals
St Albans, Australia
Shirley Wong
Recruiting
Calvary Mater Newcastle
Waratah, Australia
Lucy Corke
Not, yet, recruiting

Brazil

Fundação Pio Xii - Hospital de Câncer de Barretos
Barretos, Brazil
Rodrigo Ferreira
Not, yet, recruiting
Hospital Mario Penna
Belo Horizonte, Brazil
Graziella Martins
Not, yet, recruiting
Oncocentro de Minas Gerais
Belo Horizonte, Brazil
Flavio Cárcano
Not, yet, recruiting
Cpam - Centro de Pesquisas Da Amazônia
Belém, Brazil
Bruno Fernandes
Not, yet, recruiting
Hospital Tacchini
Bento Gonçalves, Brazil
ANDRE REIRIZ
Not, yet, recruiting
Centro Integrado de Oncologia de Curitiba
Curitiba, Brazil
Karina Vianna
Not, yet, recruiting
Iop Pesquisa
Curitiba, Brazil
Ronald Kool
Not, yet, recruiting
Centro Paraibano de Oncologia - Oncoclínicas
João Pessoa, Brazil
Juliana Fagundes
Not, yet, recruiting
Hospital de Cancer de Londrina
Londrina, Brazil
Mariana Kiara
Not, yet, recruiting
Liga Norte Riograndense Contra O Câncer
Natal, Brazil
Andrea Gomes
Not, yet, recruiting
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Brazil
Alan Azambuja
Not, yet, recruiting
Hospital Nossa Senhora Da Conceição
Porto Alegre, Brazil
Gustavo Alves
Not, yet, recruiting
Hospital São Lucas Da Pucrs
Porto Alegre, Brazil
Mahira Rosa
Not, yet, recruiting
Instituto D'Or Pesquisa E Ensino
Rio de Janeiro, Brazil
Daniel Herchenhorn
Not, yet, recruiting
Instituto Nacional de Câncer José Alencar Gomes Da Silva - Inca
Rio de Janeiro, Brazil
pedro domingues
Not, yet, recruiting
Clinica Amo - Rio Vermelho
Salvador, Brazil
Augusto Mota
Not, yet, recruiting
Nucleo de Oncologia Da Bahia
Salvador, Brazil
Andre Lima
Not, yet, recruiting
Instituto de Oncologia Saint Gallen
Santa Cruz do Sul, Brazil
Bianca Correa Tabajara Weiss
Not, yet, recruiting
Centro de Oncologia - Ceon+ - Unidade São Caetano Do Sul
São Caetano do Sul, Brazil
Suelen Martins
Not, yet, recruiting
Centro Paulista de Oncologia Clínica
São Paulo, Brazil
Denis Leonardo Fontes Jardim
Not, yet, recruiting
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
Ariel Kann
Not, yet, recruiting
Hospital Bp
São Paulo, Brazil
Fabio Schutz
Not, yet, recruiting
Ibcc - Núcleo de Pesquisa E Ensino
São Paulo, Brazil
Felipe José Cruz
Not, yet, recruiting
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, Brazil
Jose Mauricio Mota
Not, yet, recruiting
Instituto Do Cancer Arnaldo Vieira de Carvalho
São Paulo, Brazil
Patricia Marubayashi
Not, yet, recruiting

Canada

Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Canada
Nimira Alimohamed
Not, yet, recruiting
Hamilton Health Sciences-Juravinski Cancer Centre
Hamilton, Canada
Arani Sathiyapalan
Not, yet, recruiting
Centre Intégré de Cancérologie Du Chu de Québec Université Laval, Hôpital de L'Enfant-Jésus
Québec, Canada
Antoine Morin Coulombe
Not, yet, recruiting
Bc Cancer Vancouver
Vancouver, Canada
Bernhard Eigl
Not, yet, recruiting

China

Beijing Cancer Hospital
Beijing, China
Jun Guo
Recruiting
Beijing Gobroad Hospital
Beijing, China
Chuanliang Cui
Recruiting

250 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →Vepugratinib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Dec 2025
Primary completion: 31 Oct 2029
Completion: 31 May 2033
Last update posted: 21 Aug 2026
Registered enrollment: 450
Registry id: NCT07218380

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-522855-25-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.